Related Experiment Video

Updated: Jun 6, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

[Cardiovascular diseases, antiplatelet agents, anticoagulants and hemorrhagic risk]

Jorge Eusébio1, Jean-Luc Reny, Pierr Fontana

  • 1Service de médecine interne générale, Département de médecine interne, HUG, 1211 Genève 14. Jorge.Eusebio@hcuge.ch

Revue Medicale Suisse
|December 4, 2010
PubMed

Insights

Antiplatelet and anticoagulant therapies carry bleeding risks often underestimated in real-world use. Identifying high-risk patients is crucial for safe treatment strategies involving these medications.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Cardiovascular Research

Context:

  • Established benefits of antiplatelet and anticoagulant therapies contrast with underestimated bleeding risks in clinical practice.
  • Increasing use of combination therapies raises concerns due to limited data on efficacy and safety.
  • Accurate identification of patients at high risk for bleeding is paramount for effective management.

Purpose:

  • To critically evaluate the risk-benefit profile of individual and combination antiplatelet and anticoagulant treatments.
  • To provide an overview of existing clinical scores for stratifying bleeding risk.
  • To inform clinical decision-making regarding antithrombotic therapy.

Summary:

  • Bleeding complications associated with antiplatelet and anticoagulant drugs are frequently underestimated compared to real-world incidence.
  • Many patients are prescribed combined antiplatelet or anticoagulant regimens with uncertain benefits and lacking safety data.
  • This review discusses the risk-benefit of various antithrombotic agents and presents tools for bleeding risk stratification.

Impact:

  • Aims to improve patient safety by highlighting underappreciated bleeding risks.
  • Guides clinicians in selecting appropriate antithrombotic therapies, especially in combination regimens.
  • Facilitates personalized medicine approaches by enabling better bleeding risk assessment.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.